Showing results (31-40 of 133) with videos related to
Sort By:
Pageof 14
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|February 25, 2014
Treating rheumatoid arthritis to target: a Canadian patient surveyBoulos Haraoui, William Bensen, Carter Thorne, et al.Current Medical Research and Opinion|March 26, 2009
Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational studyClifton O Bingham, Akgun Ince, Boulos Haraoui, et al.Arthritis Care & Research|March 20, 2013
Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trialJanet E Pope, Boulos Haraoui, Emmanouil Rampakakis, et al.Arthritis Research & Therapy|June 8, 2019
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registryDenis Choquette, Louis Bessette, Evo Alemao, et al.Arthritis Research & Therapy|December 17, 2017
Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatmentJeffrey R Curtis, Kevin Winthrop, Cathy O'Brien, et al.Clinical and Experimental Rheumatology|April 30, 2013
Achieving remission in clinical practice: lessons from clinical trial dataVivian P Bykerk, Edward C Keystone, Bindee Kuriya, et al.Rheumatology (Oxford, England)|October 20, 2019
An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDsJanet Pope, Emmanouil Rampakakis, Julie Vaillancourt, et al.Rheumatology and Therapy|March 13, 2019
Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional StudiesBoulos Haraoui, Gustavo Casado, László Czirják, et al.Clinical Rheumatology|December 18, 2008
Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritisAnthony Russell, Ariel Beresniak, Louis Bessette, et al.Annals of the Rheumatic Diseases|August 28, 2013
The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritisJanet E Pope, Boulos Haraoui, J Carter Thorne, et al.Pageof 14